10-KPeriod: FY2014

DEXCOM INC Annual Report, Year Ended Dec 31, 2014

Filed February 25, 2015For Securities:DXCM

Summary

DexCom, Inc. (DXCM) is a medical device company focused on continuous glucose monitoring (CGM) systems for diabetes management. In their 2014 10-K filing, the company highlights the significant progress made with their G4 PLATINUM system, including FDA approval for a pediatric indication and expanded professional use. The launch of the G4 PLATINUM with Share in early 2015 further enhances the product's appeal by enabling remote monitoring. The company is navigating a rapidly growing market driven by the increasing prevalence of diabetes and the recognized benefits of improved glycemic control through CGM. While revenue has grown substantially, DexCom continues to operate at a loss, investing heavily in research and development, sales, and marketing to expand its market reach and product pipeline. Key challenges include achieving broader third-party reimbursement, managing manufacturing scale-up, and competing with established players in the medical device industry. Despite these challenges, DexCom's focus on innovation and strategic partnerships positions it for continued growth in the diabetes technology sector.

Financial Highlights

52 data points
Beta

Revenue

$257.10M

68.6% Gross Margin

Net Income

-$22.40M

-8.7% Net Margin

EPS (Diluted)

$-0.07

Total Assets

$184.60M

Cash & Equivalents

$71.80M

Free Cash Flow

$7.40M

Financial Statements
Beta
Revenue$257.10M
Cost of Revenue$82.30M
Gross Profit$176.30M
R&D Expenses$69.40M
SG&A Expenses$128.40M
Operating Expenses$197.80M
Operating Income-$21.50M
Interest Expense$800K
Net Income-$22.40M
EPS (Basic)$-0.07
Shares Outstanding (Basic)300.80M

Key Highlights

  • 1The company's flagship product, the G4 PLATINUM continuous glucose monitoring system, received FDA approval for pediatric use in February 2014 and for professional use in June 2014. This expands the addressable market and enhances its utility for healthcare providers.
  • 2DexCom received FDA approval for the G4 PLATINUM with Share system on January 23, 2015, enabling remote monitoring by up to five designated 'followers' via an iPhone app, significantly enhancing patient connectivity and caregiver support.
  • 3Product revenue saw substantial growth, increasing to $257.1 million in 2014 from $157.1 million in 2013, driven by increased sales volume of the G4 PLATINUM system and a favorable sales mix.
  • 4Despite revenue growth, DexCom reported a net loss of $22.4 million for the year ended December 31, 2014, continuing a trend of net losses since inception, reflecting significant investments in R&D and commercialization.
  • 5The company is actively pursuing partnerships, including collaborations with Animas and Tandem Diabetes Care, to integrate its CGM technology into insulin pump systems, aiming to provide a more comprehensive diabetes management solution.
  • 6Reimbursement remains a key focus, with seven major private payers having coverage policies for CGM devices, and DexCom having negotiated contracted rates with six of them. However, Medicare national coverage is still pending.
  • 7The company continues to invest heavily in research and development ($69.4 million in 2014) and selling, general, and administrative expenses ($128.4 million in 2014) to support product innovation and market expansion.

Frequently Asked Questions

DexCom's primary product is the G4 PLATINUM continuous glucose monitoring (CGM) system. Key features include its ability to monitor glucose levels for up to seven days, display real-time values and trend information, provide alerts for high or low glucose levels, and connect wirelessly to a receiver. The 'with Share' functionality allows glucose data to be transmitted to designated followers (e.g., family members, caregivers) via a mobile app.

The main revenue driver is the sale of the G4 PLATINUM system and its disposable sensors. Product revenue has shown strong year-over-year growth, increasing significantly in 2014. However, the company has consistently reported net losses since inception, reflecting substantial investments in research and development, sales, and marketing necessary to capture market share in the growing but competitive CGM landscape.

Key challenges include the need to secure broader reimbursement from third-party payors and Medicare, which is crucial for widespread adoption. The company also faces intense competition from established medical device companies. Manufacturing scale-up to meet growing demand, navigating complex regulatory environments (FDA approvals), and potential product liability claims are also significant risks. Furthermore, the G4 PLATINUM system, while advanced, is more invasive than traditional finger-stick methods and requires user adoption.

DexCom's growth strategy focuses on establishing its technology platform as the leader in CGM, driving adoption through its direct sales force and distribution partners, and expanding its product line through R&D and strategic partnerships. Key initiatives include developing integrated CGM-insulin pump systems, expanding indications for use (e.g., pediatric, professional use), seeking broad reimbursement coverage, and leveraging data management platforms like SweetSpot to enhance patient outcomes and product utilization.